ScholarIQanswers from OpenAlex

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

PaperCitations, authors & open-access status

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is a paper indexed in ScholarIQ from OpenAlex.

How many citations does High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib have?

ScholarIQcitation count

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has 82 citations in the OpenAlex counts ScholarIQ stores.

When was High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib published?

ScholarIQyear

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has 2021 year in the ScholarIQ index.

What is the open-access status of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

ScholarIQoa status

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has bronze oa status in the ScholarIQ index.

What is the DOI of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

ScholarIQdoi

The DOI for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

What is the PMID of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

ScholarIQpmid

The PMID for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

What is the OpenAlex record for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

ScholarIQopenalex

The OpenAlex for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial